Toxicity Profile of Panobinostat as seen in the PANORAMA Trial

Andrzej Jakubowiak, MD, PhD
Published Online: August 22, 2014
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Clinical Pearls:
  • In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm.
  • A higher rate of thrombocytopenia and other hematological toxicities were also seen in the panobinostat arm.
  • However, all of the toxicities were mostly manageable and did not impact the outcome of the trial.
  • More details are needed to get a better understanding of the toxicity profile of this combination in this setting.

Related Articles
Carfilzomib (Kyprolis) doubled progression-free survival (PFS) versus bortezomib (Velcade) in patients with relapsed multiple myeloma in the phase III ENDEAVOR trial.
The FDA has approved panobinostat (Farydak) in combination with bortezomib (Velcade) and dexamethasone for patients with previously treated multiple myeloma.
Lenalidomide (Revlimid) plus dexamethasone has been approved by the FDA for the treatment of newly diagnosed patients with multiple myeloma who are not candidates for stem cell transplant, based on findings from the phase III FIRST trial.
Amgen and its subsidiary Onyx Pharmaceuticals have submitted an sNDA to the FDA for the full regulatory approval of carfilzomib (Kyprolis) as a treatment for patients with relapsed multiple myeloma.
JTT Articles
Soft Tissue Sarcomas: Emerging and Novel Concepts
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
External Resources

MJH Associates
Pharmacy Times
Specialty Pharmacy Times
Physicians' Education Resource
Internal Resources

Targeted Communications
Connect With Us:

About Us
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2015
Intellisphere, LLC. All Rights Reserved.